GlassScriptPhysician profile
Jacqueline Castle
NPI 1255040663
$1,973.64
in general payments reported to CMS, 2019-2025
27 companies · $943 in 2025
The $943 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $444 · 2024: $586 · 2025: $943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $281.62 | 2023-2025 | Rexulti |
| Dexcom, INC. | $174.21 | 2023-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $173.56 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $137.02 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $120.70 | 2024-2025 | Jardiance, Kisunla, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.59 | 2023-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $97.26 | 2024-2025 | Wegovy, Ozempic |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $85.10 | 2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $84.36 | 2024-2025 | |
| Exact Sciences Corporation | $75.36 | 2023-2024 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $73.02 | 2023 | Gvoke Hypopen |
| Amgen INC. | $64.44 | 2025 | Otezla, Repatha, Prolia |
| Pfizer INC. | $55.13 | 2023-2025 | |
| Glaxosmithkline, LLC. | $54.62 | 2025 | Shingrix |
| Esperion Therapeutics, INC. | $50.54 | 2025 | Nexletol |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.62 | 2023-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $41.17 | 2023-2025 | |
| Lundbeck LLC | $39.17 | 2024-2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $38.77 | 2025 | |
| Boston Scientific Corporation | $32.09 | 2025 | General - Pain Management |
| Corcept Therapeutics | $24.12 | 2025 | Korlym |
| Shield Therapeutics INC | $23.79 | 2024 | |
| Dynavax Technologies Corporation | $22.62 | 2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $21.01 | 2024 | Auvelity |
| Phathom Pharmaceuticals, INC. | $17.39 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $14.89 | 2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $14.47 | 2024 | Capvaxive, Gardasil 9, Gardasil |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Castle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.